BHP Group Ltd (ASX: BHP) is one of the most popular blue chips on the ASX. I’d much rather invest in blue chip healthcare shares.
BHP is a big dividend payer for Australian investors, but I’m not sure how much further BHP can grow considering how big it already is. The other reason I’m not interested in buying BHP, aside from the current high valuation, is that its earnings can’t consistently grow because of resource prices.
I’d rather buy these two ASX healthcare shares:
Ramsay Health Care Limited (ASX: RHC)
Ramsay is one of the largest private hospital operators in the world with its hospital networks in Australia and Europe.
Australia is one of many countries facing ageing demographics. The number of people in retirement is expected to rise by around 40% over the next decade and 70% over the next two decades.
Sadly, the older we get the more likely medical treatment will be needed. Ramsay is a clear beneficiary from this trend as it expands it hospital network through expansions, greenfield builds and acquisitions.
As a bonus, it has increased its dividend every year since 2000. It’s currently trading at 23x FY21’s estimated earnings.
CSL Limited (ASX: CSL)
CSL is Australia’s biggest healthcare business with a global research & development footprint, there are several locations in both Europe and the US.
One of the best reasons to like CSL is that it’s constantly investing heavily into research and development, spending around 10% to 11% of global revenue on R&D each year. In FY19 it spent US$832 million with a big increase in spending on new products.
There is a constant pipeline of new biotherapies coming onto the market and new regional regulatory approvals.
CSL’s products are an important part of our society and are much more defensive than resource prices.
It’s currently trading at 35x FY21’s estimated earnings with a dividend yield of around 1%.
I’d definitely prefer CSL and Ramsay over BHP at the current share prices. Looking over the next three to five years I think I’d prefer Ramsay, but it’s hard to bet against CSL.
The post Forget BHP! I’d rather buy these blue chip healthcare shares instead appeared first on Motley Fool Australia.
These healthcare shares along with these top growth shares are some of the best ideas on the ASX right now.
Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020